Home Biosimilar Antibodies Others Others Glenzocimab (Anti-GP6 / Glycoprotein-6)
For research use only. Not for use in humans.

Glenzocimab (Anti-GP6 / Glycoprotein-6)

Synonyms: GPVI， Glycoprotein VI

Glenzocimab (Anti-GP6 / Glycoprotein-6) is a Fab fragment of humanized anti-GPVI monoclonal antibody. Glenzocimab inhibits collagen-induced platelet aggregation. Glenzocimab has the potential for the research of acute ischemic stroke. MW: 145.5 KD.

Glenzocimab (Anti-GP6 / Glycoprotein-6)

Quality Control

Batch: A247801 Purity: 99% Protein concentration: 7.28mg/ml Endotoxin Level: ＜1EU/mg
99

Mechanism of Action

Description
Glenzocimab (Anti-GP6 / Glycoprotein-6) is a Fab fragment of humanized anti-GPVI monoclonal antibody. Glenzocimab inhibits collagen-induced platelet aggregation. Glenzocimab has the potential for the research of acute ischemic stroke. MW: 145.5 KD.

Product Details

CAS No. 2101829-58-5
Molecular Weight 145.5 kDa
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT06437431 NOT_YET_RECRUITING Drug: glenzocimab|Drug: placebo Acute Ischemic Stroke Fondation Ophtalmologique Adolphe de Rothschild 2026-09 PHASE2; PHASE3
NCT05559398 COMPLETED Drug: Glenzocimab|Drug: Placebo Stroke, Acute; Stroke, Ischemic Assistance Publique - Hôpitaux de Paris 2023-01-03 PHASE2; PHASE3
NCT05070260 COMPLETED Drug: Intravenous glenzocimab (ACT017) 1000 mg|Drug: Intrave Acute Ischemic Stroke Acticor Biotech 2021-09-23 PHASE2; PHASE3
NCT04659109 COMPLETED Drug: glenzocimab|Drug: Placebo SARS-CoV Infection; Acute Respiratory Distress Syndrome; COVID-19; ARDS Acticor Biotech 2020-12-16 PHASE2

(data from https://clinicaltrials.gov, updated on 2025-06-25)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.